Vasostatin-1：回肠和胰腺神经内分泌肿瘤的新型循环生物标志物

数据集获取（Figshare）

• 源站标题：Vasostatin-1: A novel circulating biomarker for ileal and pancreatic neuroendocrine neoplasms
• DOI：10.1371/journal.pone.0196858
• 发布日期：2018-05-03
• 文件数：3 个
• 文件总体积：225.84 KB
• 源站页面：https://plos.figshare.com/articles/dataset/Vasostatin-1_A_novel_circulating_biomarker_for_ileal_and_pancreatic_neuroendocrine_neoplasms/6219158

命令行下载

curl -L -o "S1 Table.docx" "https://ndownloader.figshare.com/files/11316479"
curl -L -o "S2 Table.docx" "https://ndownloader.figshare.com/files/11316488"
curl -L -o "S3 Table.docx" "https://ndownloader.figshare.com/files/11316491"

文件清单

• S1 Table.docx（61.68 KB）
• S2 Table.docx（89.96 KB）
• S3 Table.docx（74.19 KB）

文件总体积 225.84 KB（源站 API 实测）。

数据说明

Background
Chromogranin A (CgA) is a plasma biomarker widely used in the follow-up of patients with neuroendocrine neoplasms (NENs). However, its accuracy as a tumor biomarker is relatively low because plasma CgA can increase also in patients with other diseases or in subjects treated with proton-pump inhibitors (PPIs), a class of widely-used drugs.
Methods
In the attempt to identify a more reliable biomarker for NENs, we investigated, by ELISA, the circulating levels of full-length CgA (CgA1-439) and of various CgA-derived fragments in 17 patients with ileal or pancreatic NENs, 10 healthy controls, and 21 healthy volunteers before and after treatment with PPIs.
Results
Patients with ileal or pancreatic NENs showed increased plasma levels of total-CgA and CgA1-76 fragment (vasostatin-1, VS-1) compared to controls [median (25th-75th-percentiles); total-CgA: 1.85 nM (1.01–4.28) vs 0.75 nM (0.52–0.89), p = 0.004; VS-1: 2.76 nM (1.09–7.10) vs 0.29 nM (0.26–0.32), p1-439 or CgA1-373 fragment. VS-1 positively correlated with total-CgA (r = 0.65, pp = 0.067). Treatment of patients with somatostatin analogues decreased both total-CgA and VS-1. In contrast, administration of PPIs increased the plasma levels of total-CgA, but not of VS-1.
Conclusion
These findings suggest that plasma VS-1 is a novel biomarker for ileal and pancreatic NENs. Considering that VS-1 is a well-defined fragment not induced by proton-pump inhibitors, this polypeptide might represent a biomarker for NENs diagnosis and follow-up more accurate and easier to standardize than CgA.

许可

CC BY 4.0

引用

学术使用请引用 DOI 10.1371/journal.pone.0196858（source: https://plos.figshare.com/articles/dataset/Vasostatin-1_A_novel_circulating_biomarker_for_ileal_and_pancreatic_neuroendocrine_neoplasms/6219158）。